With key tax credit under microscope, biotech firms say it should stay, be improved

But not everyone is happy with the SR&ED program. Critics say it’s ineffective and complicated.

Paul Lem, CEO and founder of the Ottawa-based biotechnology company Spartan Bioscience, has gotten back millions of dollars from the SR&ED tax-credit program over the years. The Hill Times photograph by Sam Garcia

News

BY EMILY HAWS

September 20, 2017

As the federal government starts reviewing a tax credit key to the biotechnology sector, some industry representatives say they’re happy with it but would like to see its eligibility expanded, whereas others think documentation standards are too high. The Scientific Research and Experimental Deve...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Tuesdays: Innovation & Industry Newsletter

The policies, decisions, and people working on investment and regulation in the industry and innovation realm.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy